FREQUENCY OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR, AND HER2/NEU EXPRESSION IN BREAST CANCER PATIENTS AT QUETTA – A HOSPITAL-BASED STUDY
DOI:
https://doi.org/10.70520/kjms.v18i4.711Keywords:
Hormone receptors, Modified radical mastectomy, Triple negative breast cancersAbstract
Objective: To determine the frequency of Estrogen receptor (ER), Progesterone receptor (PR) and HER2/Neu expression in breast cancer patients.
Methods: Retrospective observational study conducted at Combined Military Hospital, Quetta, from 01 Jan 2022 to 30 March 2025. The study included 100 patients aged 22 to 88 years, all with comprehensive clinical and histopathological data. Data analysis was performed using SPSS version 20, employing chi-square tests to evaluate associations. Statistical significance was determined at p<0.05.
Results: Among the 100 patients, 91% (n=91) were diagnosed with Invasive ductal carcinoma (IDC NST), followed by 4% (n=4) with Invasive lobular carcinoma (ILC), 4% (n=4) with Mucinous carcinoma, and 1 case of Metaplastic carcinoma. ER was positive in 64% (n=64) of cases, PR was positive in 54% (n=54), and Her2 was positive in 24% (n=24). Of these cases, 54% (n=54) were ER+/PR+, 12% (n=12) were ER+/PR-, 1 case was ER-/PR+, and 33% (n=33) were negative for both ER and PR, including 20% (n=20) cases of triple-negative breast cancer (TNBC). Hormone receptor expression was analyzed in relation to different age groups, histological subtypes, and histological grades.
Conclusion: The study identified a significant correlation between histological grade and hormone receptor expression with lower grades exhibiting higher hormone receptor positivity. However, no statistically significant association was observed between hormone receptor expression and histological subtype or specific age groups.
Keywords: Hormone receptors, Modified radical mastectomy, Triple negative breast cancers
References
1. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. The British Journal of Radiology. 2021;95(1130). doi:10.1259/bjr.20211033
2. Newman L. Oncologic anthropology: Global variations in breast cancer risk, biology, and outcome. Journal of Surgical Oncology. 2023;128(6):959-966. doi:10.1002/jso.27459
3. Shang C, Xu D. Epidemiology of Breast Cancer. Oncologie. 2022;24(4):649-663. doi:10.32604/oncologie.2022.027640
4. Huang J, Yuan J, Lok V, et al. Cancer Incidence and Mortality in Asian Countries: A Trend Analysis. Cancer Control. 2022;29(10):107327482210959. doi:10.1177/10732748221095955
5. Shoukat Z, Shah A. Breast Cancer Awareness and Associated Factors among Women in Pakistan: A Cross-Sectional Descriptive Study. Asian Pacific Journal of Cancer Prevention. 2023;24(5):1561-1570. doi:10.31557/apjcp.2023.24.5.1561
6. Chughtai N, Karani S, Perveen K, et al. National cervical cancer burden estimation through systematic review and analysis of publicly available data in Pakistan. BMC Public Health. 2023;23(1). doi:10.1186/s12889-023-15531-z
7. Elleson KM, Chintapally N, Laronga C, et al. Factors Predictive of Positive Lymph Nodes for Breast Cancer. Current Oncology. 2023;30(12):10351-10362. doi:10.3390/curroncol30120754
8. Abdulla HA, Nazzal K, Ahmed SA, et al. Risk Factors Associated With Sentinel Lymph Node Metastasis in Clinically Node-Negative Breast Cancer. European Journal of Breast Health. 2023;19(3):229-234. doi:10.4274/ejbh.galenos.2023.2023-3-5
9. Moldoveanu D, Schulze AK, Day CN, Goetz MP, Boughey JC, Hoskin TL. Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer. Annals of surgical oncology. 2023;30(11):6475-6483. doi:10.1245/s10434-023-13846-0
10. Pegram M, Johnston SRD, Jackisch C. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. npj Breast Cancer. 2023;9(1). doi:10.1038/s41523-023-00533-2
11. Dauphine C, Moazzez A, Chlebowski RT, Neal JC, Ozao-Choy J. Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. Annals of Surgical Oncology. 2020;27(12):4687-4694. doi:10.1245/s10434-020-08898-5
12. Yang M, Sun J, Liu L, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Scientific Reports. 2023;13(1). doi:10.1038/s41598-023-39372-3
13. Manjunath M, Choudhary B. Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncology Letters. 2021;22(1). doi:10.3892/ol.2021.12773
14. Shehzad K, Alam S, Shams MU, Riaz S, Khan HA, Khan RU. Frequency and Pathologic Features of Triple Negative Breast Cancer at A Tertiary Care Hospital in Pakistan. APMC 2021;15(2):136-8. DOI: 10.29054/APMC/2021.1160
15. Kim J, Park WC, Jung SP, et al. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type. Breast Cancer Research and Treatment. 2020;184(2):527-542. doi:10.1007/s10549-020-05861-
16. Mouabbi JA, Hassan A, Hortobagyi GN, Lim B, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Research and Treatment. 2022;193(2):253-264. doi:10.1007/s10549-022-06572-w
17. Park WK, Ryu JM, Yu J, et al. The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Cancers. 2023;15(22):5361. doi:10.3390/cancers15225361
18. Parkinson B, Li Z, Parwani AV, Shen T, Chen W. TRPS1 Expression in Breast Carcinomas: Focusing on Metaplastic Breast Carcinomas. American Journal of Surgical Pathology. 2021;46(3):415-423. doi:10.1097/pas.0000000000001824
19. Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA network open. 2024;7(1):e2353331. doi:10.1001/jamanetworkopen.2023.53331
20. Kwak Y, Nam SJ, Shin DS, et al. Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study. Cancers. 2023;15(13):3435. doi:10.3390/cancers15133435
21. Kumamaru H, Kinukawa N, Tanakura K, et al. 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan. Breast cancer (Tokyo, Japan). 2024;31(2):179-184. doi:10.1007/s12282-023-01532-8
22. Svanøe AA, Kvamme AB, Tegnander AF, et al. Age-related phenotypes in breast cancer: A population-based study. International Journal of Cancer. 2024;154(11):2014-2024. doi:10.1002/ijc.34863
23. Park WK, Ryu JM, Yu J, et al. The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Cancers. 2023;15(22):5361. doi:10.3390/cancers15225361
24. Yoder R, Pluenneke R, Staley JM, et al. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. npj Breast Cancer. 2022;8(1). doi:10.1038/s41523-022-00448-4
25. Mohsin RN, Mohamad BJ. Clinical and Histopathological Features of Breast Cancer in Iraqi Patients between 2018-2021. Iraqi Journal of Science. Published online January 30, 2024:90-107. doi:10.24996/ijs.2024.65.1.9
